XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.2

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)

6 Months Ended

Jun. 30, 2022

Concentration Risk And Geographic Information [Abstract]

Schedule of Net Product Revenues by Product

The following table disaggregates total Net Product Revenues by product.

			Three Months Ended June 30,												Six Months Ended June 30,
			2022						2021						2022						2021
Net product revenues by product:
Vimizim			$	173,206					$	171,655					$	356,265					$	329,953
Naglazyme			115,783						118,813						243,814						226,149
Palynziq			61,643						58,935						116,528						112,973
Kuvan			57,602						78,807						116,939						149,570
Brineura			37,725						30,332						73,898						57,657
Voxzogo			34,374						—						54,032						—
Total net product revenues marketed by the Company			480,333						458,542						961,476						876,302
Aldurazyme net product revenues marketed by Sanofi			37,327						28,128						61,709						78,137
Total net product revenues			517,660						486,670						1,023,185						954,439
Royalty and other revenues			16,138						15,023						29,972						33,284
Total revenues			$	533,798					$	501,693					$	1,053,157					$	987,723

Schedule of Total Net Product Revenues Based on Patient Location

The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for Aldurazyme, which is sold exclusively by Sanofi worldwide.

			Three Months Ended June 30,												Six Months Ended June 30,
			2022						2021						2022						2021
United States			$	169,838					$	169,411					$	320,653					$	324,474
Europe			161,230						166,704						318,062						315,576
Latin America			89,911						42,248						152,455						101,953
Rest of world			59,354						80,179						170,306						134,299
Total net product revenues marketed by the Company			$	480,333					$	458,542					$	961,476					$	876,302
Aldurazyme net product revenues marketed by Sanofi			37,327						28,128						61,709						78,137
Total net product revenues			$	517,660					$	486,670					$	1,023,185					$	954,439

Schedule of Net Product Revenue Concentrations Attributed to Largest Customers

The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 

			Three Months Ended June 30,												Six Months Ended June 30,
			2022						2021						2022						2021
Customer A			16		%				16		%				16		%				16		%
Customer B			12		%				13		%				12		%				13		%
Customer C			5		%				12		%				5		%				10		%
Total			33		%				41		%				33		%				39		%

X

- Definition

Concentration risk and geographic information.

+ References

No definition available.

+ Details

Name:	bmrn_ConcentrationRiskAndGeographicInformationAbstract
Namespace Prefix:	bmrn_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration